Olympus is a medical-device maker with a leading position in the endoscope market and a diversified global revenue stream... Show more
OLYMY moved above its 50-day moving average on November 21, 2025 date and that indicates a change from a downward trend to an upward trend. In of 26 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for OLYMY just turned positive on November 24, 2025. Looking at past instances where OLYMY's MACD turned positive, the stock continued to rise in of 29 cases over the following month. The odds of a continued upward trend are .
The 10-day moving average for OLYMY crossed bullishly above the 50-day moving average on October 24, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 9 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where OLYMY advanced for three days, in of 162 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 101 cases where OLYMY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Momentum Indicator moved below the 0 level on November 26, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on OLYMY as a result. In of 56 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OLYMY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
OLYMY broke above its upper Bollinger Band on November 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. OLYMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.189) is normal, around the industry mean (63.447). P/E Ratio (24.716) is within average values for comparable stocks, (37.281). OLYMY's Projected Growth (PEG Ratio) (4.172) is slightly higher than the industry average of (1.722). Dividend Yield (0.010) settles around the average of (0.019) among similar stocks. P/S Ratio (2.449) is also within normal values, averaging (35.876).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OLYMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Industry MedicalNursingServices
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| THW | 12.98 | 0.25 | +1.96% |
| abrdn World Healthcare Fund | |||
| ARMG | 9.02 | 0.16 | +1.85% |
| Leverage Shares 2X Long Arm Daily ETF | |||
| DFSV | 32.52 | 0.17 | +0.53% |
| Dimensional US Small Cap Value ETF | |||
| MAYT | 36.49 | 0.04 | +0.12% |
| AllianzIM U.S. Large Cp Buffer10 May ETF | |||
| ECML | 33.37 | N/A | N/A |
| Euclidean Fundamental Value ETF | |||
A.I.dvisor indicates that over the last year, OLYMY has been loosely correlated with OCPNF. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if OLYMY jumps, then OCPNF could also see price increases.
| Ticker / NAME | Correlation To OLYMY | 1D Price Change % | ||
|---|---|---|---|---|
| OLYMY | 100% | +1.12% | ||
| OCPNF - OLYMY | 42% Loosely correlated | N/A | ||
| TRUMY - OLYMY | 42% Loosely correlated | +1.41% | ||
| MTD - OLYMY | 35% Loosely correlated | -1.29% | ||
| SSMXY - OLYMY | 34% Loosely correlated | -0.98% | ||
| HOCPY - OLYMY | 33% Loosely correlated | +1.98% | ||
More | ||||
| Ticker / NAME | Correlation To OLYMY | 1D Price Change % |
|---|---|---|
| OLYMY | 100% | +1.12% |
| Medical/Nursing Services industry (215 stocks) | 22% Poorly correlated | +1.89% |
| Health Services industry (422 stocks) | -4% Poorly correlated | +1.36% |